The forecast for the number of multidrug-resistant tuberculosis (MDR-TB) cases started on treatment in the US shows a steady upward trend from 2024 to 2028, beginning with 102 cases in 2024 and reaching 107 cases by 2028. This period of forecasted data suggests incremental growth, with a calculated Compound Annual Growth Rate (CAGR). Although specific data for 2023 isn't provided, the upward trend indicates a focus on enhancing treatment accessibility and detection.

Future trends to watch for:

Potential advancements in MDR-TB treatment options and their impact on case management.
Increased investment in public health initiatives to prevent the spread of MDR-TB.
Monitoring policy changes that could influence treatment program funding or access.